Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model

被引:14
|
作者
Zhuang, Luning [1 ,2 ]
Sy, Sherwin K. B. [2 ]
Xia, Huiming [3 ]
Singh, Rajendra P. [2 ]
Mulder, Midas B. [2 ]
Liu, Changxiao [4 ]
Derendorf, Hartmut [2 ]
机构
[1] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China
[2] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
[3] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA
[4] Tianjin Inst Pharmaceut Res, Key Lab Drug Delivery Technol & Pharmacokinet, Tianjin 300193, Peoples R China
关键词
Time-kill curve; PK/PD modelling; Vertilmicin; Combination therapy; DIFFERENT BACTERIAL STRAINS; HEALTHY-VOLUNTEERS; PROTEIN-BINDING; SERUM; DERIVATIZATION; COMBINATIONS; ANTIBIOTICS; INFECTIONS; GENTAMICIN; THERAPY;
D O I
10.1016/j.ijantimicag.2014.09.017
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aim of this study was to develop a semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) model to evaluate the in vitro synergy between vertilmicin and ceftazidime against Pseudomonasaeruginosa. The in vitro antimicrobial activity of vertilmicin alone was initially assessed by static and dynamic time-kill experiments against three bacterial strains, including MSSA, MRSA and P. aeruginosa. The combined killing effect with ceftazidime was then evaluated in a static time-kill study against P. aeruginosa. Vertilmicin displayed a concentration-dependent killing effect against the three bacterial strains, and its short half-life may possibly have a dramatic impact on antimicrobial activities. A two compartment pharmacodynamic model consisting of drug-susceptible and -resistant compartments was developed to characterise the relationship between drug exposure and bacterial response for the time-kill curves from both monotherapy and combination therapy. Loewe additivity was incorporated into the pharmacodynamic model to describe the drug-drug interactive effect in the combination therapy. For monotherapy, the estimated EC50 of the dynamic time-kill study against each strain was close to its MIC but was higher than that of the static time-kill study. The EC50 of combination therapy was estimated at 2.67 mg/L compared with 4.54 mg/L in monotherapy, indicating an enhanced bactericidal capacity. The drug-drug interactive effect was not significantly synergistic but highly varied at each specific combination. Potential synergistic combinations could be screened using PK/PD modelling and simulation. These results demonstrated that PK/PD modelling provides an innovative approach to assist dose selection of combination vertilmicin and ceftazidime for future clinical study design. (C) 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:151 / 160
页数:10
相关论文
共 50 条
  • [1] Characterization of In Vitro Antimicrobial Activity of Vertilmicin Alone and in Combination with Ceftazidime by Using Semi-mechanistic Pharmacokinetic/Pharmacodynamic Model
    Zhuang, Luning
    Sy, Sherwin K. B.
    Xia, Huiming
    Singh, Rajendra P.
    Liu, Changxiao
    Derendorf, Hartmut
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S26 - S26
  • [2] Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model
    Bergen, Phillip J.
    Bulitta, Jurgen B.
    Forrest, Alan
    Tsuji, Brian T.
    Li, Jian
    Nation, Roger L.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (09) : 3783 - 3789
  • [3] Application of Semi-Mechanistic Pharmacokinetic and Pharmacodynamic Model in Antimicrobial Resistance
    Mi, Kun
    Zhou, Kaixiang
    Sun, Lei
    Hou, Yixuan
    Ma, Wenjin
    Xu, Xiangyue
    Huo, Meixia
    Liu, Zhenli
    Huang, Lingli
    [J]. PHARMACEUTICS, 2022, 14 (02)
  • [4] Discovery of Efficacious Pseudomonas aeruginosa-Targeted Siderophore-Conjugated Monocarbams by Application of a Semi-mechanistic Pharmacokinetic/Pharmacodynamic Model
    Murphy-Benenato, Kerry E.
    Bhagunde, Pratik R.
    Chen, April
    Davis, Hajnalka E.
    Durand-Reville, Thomas F.
    Ehmann, David E.
    Galullo, Vincent
    Harris, Jennifer J.
    Hatoum-Mokdad, Holia
    Jahic, Haris
    Kim, Aryun
    Manjunatha, M. R.
    Manyak, Erika L.
    Mueller, John
    Patey, Sara
    Quiroga, Olga
    Rooney, Michael
    Sha, Li
    Shapiro, Adam B.
    Sylvester, Mark
    Tan, Beesan
    Tsai, Andy S.
    Uria-Nickelsen, Maria
    Wu, Ye
    Zambrowski, Mark
    Zhao, Shannon X.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (05) : 2195 - 2205
  • [5] Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model
    denHollander, JG
    Horrevorts, AM
    vanGoor, MLPJ
    Verbrugh, HA
    Mouton, JW
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) : 95 - 100
  • [6] Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa?: An in vitro pharmacodynamic model
    Alou, L
    Aguilar, L
    Sevillano, D
    Giménez, MJ
    Echeverría, O
    Gómez-Lus, ML
    Prieto, J
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (02) : 209 - 213
  • [7] Characterization of synergy between ofloxacin, ceftazidime, and tobramycin against Pseudomonas aeruginosa
    MadarasKelly, KJ
    Moody, J
    Larsson, A
    Hovde, LB
    Rotschafer, JC
    [J]. CHEMOTHERAPY, 1997, 43 (02) : 108 - 117
  • [8] Elucidation of the pharmacokinetic/ pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model
    Bilal, Hajira
    Peleg, Anton Y.
    McIntosh, Michelle P.
    Styles, Ian K.
    Hirsch, Elizabeth B.
    Landersdorfer, Cornelia B.
    Bergen, Phillip J.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (06) : 1570 - 1578
  • [9] Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model
    Gunderson, BW
    Ibrahim, KH
    Hovde, LB
    Fromm, TL
    Reed, MD
    Rotschafer, JC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) : 905 - 909
  • [10] Comment on: Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model
    Plant, Aiden J.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (11) : 3216 - 3217